Second phase 2/3 placebo-controlled trial of PBI-4050 in Idiopathic Pulmonary Fibrosis patients who have failed to tolerate nintedanib or pirfenidone.
Latest Information Update: 26 Jul 2022
At a glance
- Drugs Fezagepras (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- 21 Jul 2022 According to Liminal BioSciences media release, the company has discontinued development of fezagepras based on results from the Phase 1a single ascending dose ("SAD") clinical trial, which indicated fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The recommendation to stop the development program for fezagepras was not based on safety concerns.
- 21 Jul 2022 Status changed from planning to discontinued, according to a Liminal BioSciences media release.
- 10 May 2017 According to a ProMetic Life Sciences media release, the company scheduled to initiate this trial in second quarter of 2017.